Drug profile

The FDA adverse-event record for Gentamicin/Mometasone/Clotrimazole

10 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Gentamicin/Mometasone/Clotrimazole. See the species affected, top reactions, and outcomes below.

10
adverse-event reports
0.0%
death-coded share
Dog
most-reported species
4
Loose stool - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
10
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

Gentamicin/Mometasone/Clotrimazole

Administration Routes

Auricular (Otic)TopicalUnknown

Species Affected

Dog 9
Cat 1

Most Affected Breeds

Shepherd Dog - German 3
Retriever - Golden 1
Terrier - Jack Russell 1
Terrier - Yorkshire 1
Shar Pei 1
Domestic Shorthair 1
Hound (unspecified) 1
Terrier - Silky 1

Most Reported Reactions

Loose stool 4
Decreased mean corpuscular volume (MCV) 3
Decreased percentage of reticulocytes 3
Neutrophilia 3
Eosinophilia 3
Basophilia 3
Thrombocytopenia 3
Elevated alanine aminotransferase (ALT) 3
High sodium-potassium ratio (Na:K ratio) 3
Leucocytosis NOS 3
Elevated serum alkaline phosphatase (SAP) 3
Haemolysis NOS 3

Outcome Breakdown

Recovered/Normal
4 (40.0%)
Outcome Unknown
3 (30.0%)
Ongoing
3 (30.0%)

Gentamicin/Mometasone/Clotrimazole Adverse Event Insights

10 reports name Gentamicin/Mometasone/Clotrimazole; 0 recorded a death outcome (0.0% of reported events, not a population-level mortality rate). Active ingredient: Gentamicin/Mometasone/Clotrimazole. Administration routes: Auricular (Otic), Topical, Unknown.

By species: Dog (9 reports), Cat (1 reports). By breed: Shepherd Dog - German (3), Retriever - Golden (1), Terrier - Jack Russell (1).

Leading clinical signs: Loose stool (4), Decreased mean corpuscular volume (MCV) (3), Decreased percentage of reticulocytes (3), Neutrophilia (3). Outcome, 10 coded reports: Recovered/Normal leads at 40.0%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.